Indian Council of Medical Research (ICMR), India’s premier medical research organisation, issued an invitation to vaccine developers on Wednesday to work together on the creation of a vaccine against the monkeypox virus.
In order to develop in-vitro diagnostic tools and vaccine candidates for the monkeypox virus, ICMR has issued a call for expressions of interest. Monkeypox is a viral zoonosis, or a disease spread from animals to people, according to the World Health Organization. It has symptoms resembling those of smallpox patients in the past but is clinically less severe.
After receiving reports of more than 16,000 cases and five fatalities from 75 different countries, the WHO raised the alert level for monkeypox on July 23 and deemed the virus a public health emergency of international concern (PHEIC). India has four confirmed instances so far.
Fever, excruciating headache, backache, myalgia, severe asthenia, and lymphadenopathy, or enlargement of the lymph nodes, can all be signs of the viral infection. Up to five days may pass between these symptoms.
“Experienced vaccine maker or pharma businesses or R&D institutions or In-vitro Diagnostic (IVD) kit manufacturers” should be the criteria for eligibility. An organization that expresses interest must be profitable, have marketed similar items in the three years immediately previous, and not have had a net loss during those years.
The business must be able to “produce at least one lakh doses per week” in order to produce vaccines. The interest must be sent by August 10 in order to be considered.
The monkeypox virus has been isolated by ICMR and its Pune-based partner, the National Institute of Virology. It is now being propagated on certain cell lines under biosafety lab settings.
The press release issued by ICMR said, “These isolates were further purified and characterized. Tissue culture infective dose (TCID50) has been estimated and bulk propagation of the virus stock has been achieved.”